Skip to main content
Matthew Ellis, MD, Oncology, Houston, TX, St. Luke's Health - Baylor St. Luke's Medical Center

MatthewJEllisMDPhD FRCP

Oncology Houston, TX

Breast Cancer, Hematologic Oncology

Director, Lester and Sue Smith Breast Center Baylor College of Medicine, Professor of Medicine and Molecular Cell Biology, associate director, translational research Dan L Duncan Comprehensive Cancer Center

Dr. Ellis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ellis' full profile

Already have an account?

Education & Training

  • Georgetown University Hospital
    Georgetown University HospitalFellowship, Medical Oncology, 1992 - 1994
  • School of Clinical Medicine, University of Cambridge
    School of Clinical Medicine, University of CambridgeClass of 1983

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2014 - 2022
  • MO State Medical License
    MO State Medical License 2003 - 2015
  • NC State Medical License
    NC State Medical License 2001 - 2005
  • DC State Medical License
    DC State Medical License 1996 - 2004
  • MD State Medical License
    MD State Medical License 1995 - 1996

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts  
    Souzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature

Press Mentions

  • SABCS 2022: Panelists Discuss Strategies to Overcome Top Obstacles in Breast Cancer Management
    SABCS 2022: Panelists Discuss Strategies to Overcome Top Obstacles in Breast Cancer ManagementDecember 15th, 2022
  • Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
    Breast Cancer Test’s Genomic Underpinning Drives Prognostic PerformanceOctober 30th, 2020
  • Micro-Scaled Method Holds Promise as Improved Cancer Diagnostic Platform
    Micro-Scaled Method Holds Promise as Improved Cancer Diagnostic PlatformJanuary 27th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations